コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 exists between atrial fibrillation (AF) and chronic renal disease.
2 and renal vasculopathy prior to the onset of chronic renal disease.
3 tribute to accelerated microcalcification in chronic renal disease.
4 evalent in patients with atherosclerosis and chronic renal disease.
5 eases such as hepatitis, liver cirrhosis and chronic renal disease.
6 ation, coronary heart disease, diabetes, and chronic renal disease.
7 addressed the potential benefits of IL-10 in chronic renal disease.
8 and improves renal function in this model of chronic renal disease.
9 he increased synthesis of fibronectin during chronic renal disease.
10 enal injury in a variety of animal models of chronic renal disease.
11 herapy in organ remodeling diseases, such as chronic renal disease.
12 injury and, thus, can prevent progression to chronic renal disease.
13 kg + 5 x 20 mg/kg) over 12 wk induced severe chronic renal disease.
14 laying a critical role in the progression of chronic renal disease.
15 , ischemic heart disease, and progression of chronic renal disease.
16 ascular disease event rates in patients with chronic renal disease.
17 ore rapid rate of progression of nondiabetic chronic renal disease.
18 of gender on the progression of nondiabetic chronic renal disease.
19 protein restriction slows the progression of chronic renal disease.
20 hypertension, congestive heart failure, and chronic renal disease.
21 esigned to slow or arrest the progression of chronic renal disease.
22 interstitial fibrosis, eventually leading to chronic renal disease.
23 e effect of low-protein diets in humans with chronic renal disease.
24 ficiency, and cardiovascular, pulmonary, and chronic renal disease.
25 ee from prevalent cardiovascular disease and chronic renal disease.
26 involved in the physiopathology of acute or chronic renal disease.
27 volved in molecular pathways of acquired and chronic renal diseases.
28 ients with EN but not in patients with other chronic renal diseases.
29 central role in the onset and progression of chronic renal diseases.
30 o be common endpoint result of many forms of chronic renal diseases.
31 be necessary for halting the progression of chronic renal diseases.
32 ions for inhibiting the RAS in patients with chronic renal diseases.
33 rosis, and renal function in swine models of chronic renal diseases.
34 nolone exposure (adjusted odds ratio, 1.38), chronic renal disease (1.19), age 85 years (1.17), prior
35 y and mortality as well as increased risk of chronic renal disease, a finding that is especially rele
37 erulonephritis, both leading causes of human chronic renal disease, affecting 10% of the world popula
38 er prevalence rates of diabetes mellitus and chronic renal disease and are more likely to present wit
39 indirectly contributes to the progression of chronic renal disease and is an important factor in the
40 cells is associated with the development of chronic renal disease and may promote fibrogenesis by in
42 , prior MI, prior CVD, rheumatoid arthritis, chronic renal disease, and chronic obstructive pulmonary
43 rtension, diabetes, chronic cardiac disease, chronic renal disease, and malignancy in the past 5 year
44 n renal tubular epithelia in mouse models of chronic renal diseases, and such induction was spatially
45 e exposure (adjusted odds ratio [aOR] 1.38), chronic renal disease (aOR 1.19), age >85 years (aOR 1.1
46 thought to play a role in the progression of chronic renal disease, but clinical trials to date have
47 between analgesic use and increased risk of chronic renal disease, but few cohort studies have exami
49 eliorates renal fibrosis in animal models of chronic renal disease by promoting extracellular matrix
50 erulopathy (C3G) is a heterogeneous group of chronic renal diseases characterized predominantly by gl
53 ve demonstrated that 50% of individuals with chronic renal disease (CRD) die of cardiovascular causes
54 (NO) deficiency occurs and may contribute to chronic renal disease (CRD), the status of the NO system
55 6 human renal biopsy samples from a range of chronic renal diseases (CRD) to determine changes in tTg
57 as cirrhosis, non-alcoholic steatohepatitis, chronic renal disease, heart failure, diabetes, idiopath
58 iated with older age, lower body mass index, chronic renal disease, higher Sequential Organ Failure A
59 de additional protection from progression of chronic renal disease; however, there have been few long
60 9), diabetes (HR, 5.2; 95% CI, 5.0-5.6), and chronic renal disease (HR, 1.7; 95% CI, 1.5-1.9) occurre
66 suggest that the beneficial effect of HGF in chronic renal disease is attributable, at least in part,
67 c treatment of dyslipidemia in children with chronic renal disease is controversial because conclusiv
68 sease, chronic pulmonary disease and asthma, chronic renal disease, malignancy in the past 5 years, H
69 and suggests that predisposition to develop chronic renal disease may include an in utero origin.
70 ngs in children with dilated cardiomyopathy, chronic renal disease, obesity, type I diabetes, juvenil
72 deficiency was present in one third, ACI or chronic renal disease or both was present in one third,
73 t predictors of any GDMT included absence of chronic renal disease or nonsustained ventricular tachyc
75 d therapeutic intervention for patients with chronic renal disease, regardless of whether systemic hy
76 er cancer (SMR = 2.5; 95% CI: 1.6, 3.7), and chronic renal disease (SMR = 2.0; 95% CI: 1.5, 2.8).
77 llitus (SMR = 1.90, 95% CI: 1.35, 2.61), and chronic renal disease (SMR = 3.11, 95% CI: 1.66, 5.32).
78 ronic lung disease, impaired immune disease, chronic renal disease, stroke, and cancer, and for those
79 nes plays a major role in the development of chronic renal diseases such as diabetic nephropathy.
80 t cells is a key event in the progression of chronic renal diseases that leads to end-stage renal fai
81 on in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 I
82 levels in serum were measured by ELISA, and chronic renal disease was induced by a 5/6 nephrectomy (
83 ic systemic fibrosis (NSF) in the setting of chronic renal disease with associated gadolinium exposur